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Abstract
Background: Patients with a patent foramen ovale (PFO) who suffered from stroke, TIA or peripheral paradoxical
embolism are at substantial risk for recurrent neurologic events and in need for secondary prevention. Interventional
closure of PFO has been performed for over 20 years. Numerous devices have been developed and used for treatment.
We investigated PFO closure with the third generation Occlutech Figulla® Flex II Occluder device.
Methods: Between 2012 and 2015 57 patients (mean age 47.3 ± 1.5 years) who had suffered from a thromboembolic
event of unknown cause underwent transcatheter PFO closure with the Occlutech Figulla® Flex II Occluder at our
department. 68.4 % of all patients had suffered from cryptogenic stroke, while TIA had occurred in 28.1 %. Almost all
patients were diagnosed with an atrial septum aneurysm (90.9 %) and a severe right-to-left shunt grade 3: >20
microbubbles (92.0 %). Follow-up was done 6 months post intervention by clinical examination and transesophageal
contrast echocardiography.
Results: No major periprocedural or in-hospital complication occurred. Closure was sufficient with no residual
right-to-left shunt in 94.4 % of all patients at 6 months post implantation and only minimal residual shunt in
three cases. There were no thrombotic formations associated to the occluder device. Atrial fibrillation occurred in
one patient and a recurrent cerebral ischemic event was seen in one patient, who suffered from another TIA.
Conclusions: The Occlutech Figulla® Flex II Occluder device and its delivery system is safe and provides sufficient
closure of PFO in patients who suffered from cryptogenic stroke, TIA or paradoxical peripheral embolism.
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Background
Paradoxical embolism caused by a patent foramen ovale
(PFO) is considered to be an important cause of crypto-
genic ischemic stroke especially in young patients [1].
Prevalence of a PFO is up to 40 % in patients with stroke
[2]. Patients who suffered from ischemic stroke without
determined origin were shown to have larger PFO with
more extensive right-to-left interatrial shunting in con-
trast transesophageal echocardiography than patients
with determined cause [3]. Especially patients diagnosed
with a combination of PFO and atrial septum aneurysm
(ASA) and prior stroke are at substantial risk for a re-
current cerebral ischemia [4, 5]. Therapeutic options for
secondary prevention of recurrent stroke in these pa-
tients include either conservative medical treatment
(oral anticoagulation or platelet inhibition) or interven-
tional closure. Reports about the efficacy of medical
treatment to prevent recurrent stroke are diverse [4, 6].
Transcatheter closure of PFO has been shown to be
feasible over 20 years ago [7]. Recent cost-effectiveness
analysis revealed that medical treatment cost exceeded
interventional PFO closure cost at about 30 years post
implantation [8]. Over the years numerous devices with
different structures and varying anticoagulation or anti-
thrombotic therapy regimes have been used [9–12].
Controversy though still exists about the indication for
PFO closure. Three randomized clinical trials of transcath-
eter device PFO closure versus medical therapy have been
published yet [9–11]. All three failed to demonstrate
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significant superiority of interventional PFO closure
over medical management in the intention-to-treat
analysis. Per-protocol and as-treated analyses of the
RESPECT Trial though indicated superiority of PFO
closure vs. medical therapy. Subgroup post hoc ana-
lysis of the RESPECT Trial suggest that patients with
substantial right-to-left interatrial shunt or ASA seem
to profit probably most from PFO closure. As the med-
ical treatment therapy compared to PFO occlusion re-
sults in life long antiplatelet or oral anticoagulation
therapy, interventional closure is considered reasonable
by numerous physicians. Post interventional closure
rates differ depending on the device used and have
been described between 86 and 96 % [9–11, 13, 14].
The AmplatzerTM PFO Occluder (ST Jude MedicalTM,
Saint Paul, Minnesota, USA) is probable the most
widely used occluder device and was recently studied in
the two large multi-center RESPECT and PC trials.
Other devices like the GORE® HELEX® (W. L. Gore & As-
sociates, Inc, Newark, Delaware, USA), Nit-Occlud® PFO
(pfm medical ag, Cologne, Germany), Cardi-O-Fix PFO
Occluder (Starway Medical Technology, Inc, Beijing,
China) and CeraFlexTM PFO Occluder (Carlsbad, Califor-
nia, USA) are available [9, 11, 14–17]. Some devices such
as the STARFlex® (NMT Medical, Inc, Boston, Massachu-
setts, USA), studied in the CLOSURE I Trial have disap-
peared from the market [10, 12]. Occlutech (Jena,
Germany) launched their first occluder in 2003 and their
current third generation occluder device, available since
October 2011, is called Figulla® Flex II. The Figulla® PFO
devices are build out of a nitinol wire mesh, which is
shaped to two discs by a distinctive braiding technique,
which allows to reduce material in the left atrium [18].
There are four sizes with diameters 16/18, 23/25, 27/30
and 31/35 mm available. Another unique characteristic of
the Figulla® devices is the flexibility of the occluder de-
vice, which can be angled independently from the angle
of the delivery system due to a ball-socket joint connec-
tion. This enables a preferred occluder placement prior
to release of the occluder even under difficult anatomic
circumstances [19, 20]. Like previous Occlutech Figulla®
devices the Figulla Flex II has a single layer left atrial
disc and only one right atrial hub (Fig. 1a). Modifica-
tions of the delivery system allow now greater flexibility
and range of angulation and the left atrial material con-
tent is minimized providing a superior adaptation to
the interatrial septum (Fig. 1b).
In order to reevaluate our standard practice we retro-
spectively analyzed data from patients with cryptogenic
ischemic stroke, transient ischemic attack (TIA) or
paradoxical embolism, which underwent percutaneous
closure of PFO with the Figulla® Flex II Occluder device.
Methods
Patients
We retrospectively studied consecutive patients with a
history of ischemic stroke, TIA or peripheral embolism,
who were diagnosed with a PFO and underwent trans-
catheter PFO closure with the Figulla® Flex II Occluder
at our Department between November 2012 to July 2015.
Cryptogenic stroke, TIA or paradoxical embolism was di-
agnosed at the Department of Neurology or by a referring
neurologist. Cerebral imaging (computer tomography or
magnetic resonance imaging) had been performed in all
patients and at least one 12-lead EKG, echocardiography,
cardiac monitoring for at least 24 h with automated
rhythm detection and imaging of the both extracranial
and intracranial arteries had been done.
Echocardiography
Transesophageal multiplane contrast echocardiography
was performed in all patients to diagnose PFO and ASA.
For those examinations performed in our department,
Fig. 1 Pictures of the Occlutech Figulla® Flex II. a Occlutech Figulla® Flex II ball-socket right atrial hub. b Occlutech Figulla® Flex II attached to the
delivery system
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quantification of the right-to-left shunt was assessed be-
fore, during and after Valsalva maneuver, following the
graduation of the RESPECT Trial. Numbers of passing
contrast microbubbles were counted and categorized ac-
cording to the following grades: grad 0: no microbubbles,
grade 1: 1–9 microbubbles, grade 2: 10–20 microbubbles,
grade 3: >20 microbubbles as described earlier [9]. Spon-
taneous appearance of contrast was considered to be grade
3. ASA was defined by an excursion of the septum of
≥10 mm, following the RESPECT Trial as well [9]. Trans-
esophageal multiplane echocardiography cines from ex-
aminations performed by referring centers were reviewed
by the echocardiographic specialist from our department
as well as by the interventionalist and graduation of the
right-to-left shunt rated as described above. For those ex-
aminations, which were done in our department, PHILIPS
EPIQ 7 or iE33 ultrasound machines were used.
Implantation procedure
All implantation procedures were performed at the De-
partment of Cardiology and Angiology at Hannover
Medical School, Germany. The Occlutech Figulla® Flex II
Occluder device and its delivery system have been de-
scribed earlier [21]. In brief, implantation was performed
in local anesthesia and under transesophageal multiplane
echocardiography as well as fluoroscopy guidance. After
puncture of a femoral vein and passage of the PFO with
a 6 F multipurpose catheter (Cordis, Miami, Florida, USA),
the multipurpose catheter was changed to a transseptal
sheath by using a 0.032 heavy duty wire (COOK Europe,
Bjaeverskov, Denmark). The Occlutech transseptal deliver
system (8 to 9 F) was then advanced into the right atrium.
The distance from the PFO to the aortic root and the dis-
tance from the PFO to superior vena cava orifice, as well as
the PFO-defect size were measured by transesophageal
multiplane echocardiography. Size of the occluder device
(23/25 mm vs. 27/30 mm) was chosen depending on echo-
cardiographic findings. After passing the atrial septum,
implantation of the occluder was accomplished under
echocardiographic and fluoroscopic guidance. If a satisfying
device position had been achieved, the delivery system was
disconnected from the occluder. Following the implant-
ation correct positioning and sufficient closure were verified
by echocardiography with colour-doppler imaging. Success-
fully closure was considered if no or only minimal residual
shunt was detected. The delivery system was removed and
manual compression applied on the venous puncture side
until hemostasis was achieved. Thereafter patients under-
went compression bandage of the access site for 8 h.
Medical treatment
Patients received 7500 U of heparin intravenously during
the implantation procedure. Cefazolin or vancomycin, in
cases of known allergy, was used for periprocedural anti-
infective prophylaxis. Endocarditis prophylaxis was rec-
ommended for at least 6 months post implantation. Dual
antiplatelet therapy with aspirin (100 mg/die) and clopi-
dogrel (75 mg/die) was recommended for all patients
during at least the first 6 months following the procedure.
Patients received a loading dose of clopidogrel (600 mg)
the day before the procedure. Before discontinuation
of dual antiplatelet therapy thrombus formation on
the occluder device was ruled out by transesophageal
echocardiography.
Follow-up
Six months after implantation procedure patients were
requested to visit the outpatient clinic and interviewed
asking for a recurrent neurologic event or paradoxical
embolism, other adverse events such as hospitalization
or bleeding as well as occurrence of arrhythmias. Further
transesophageal contrast echocardiography was performed,
following the baseline examination procedure. Special at-
tention was paid on detection of potential residual shunts
and thrombus formation as well as accurate position of the
occluder device.
Statistics
All results are presented as mean ± standard error. Stat-
istical analyses were done using IBM SPSS Statistics
(Armonk, New York, US).
Results
Patients and echocardiography
During the period from November 2012 to July 2015 57
consecutive patients who had suffered from at least one
thromboembolic event underwent transcatheter PFO
closure with the Figulla Flex II Occluder device from
Occlutech® at our Department. As shown in Table 1
mean age at implantation was 47.3 ± 1.5 years. Previous
stroke had occurred in 68.4 % and TIA in 28.1 % of all
patients. Three patients had suffered only from recurrent
paradoxical peripheral embolism. Two patients had two
previous events, one had a TIA and a stroke while the
other patient had a history of stroke as well as of para-
doxical peripheral embolism in the right brachial artery
(Fig. 2). Nine out of ten patients presented with a coex-
isting ASA (90.9 %) and a grade 3 right-to-left shunt
(92.0 %) (Fig. 3).
Implantation procedure
Device implantation was successfully performed in all
patients. Occluder device sizes used were: 23/25 mm in
51 (89.5 %) and 27/30 mm in six patients (10.5 %). No
major procedure-related complications occurred during
the implantation.
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Follow-Up
Complete follow-up data was available for 54 patients.
Mean hospital stay was 1.5 ± 0.09 days. No major in-
hospital complication took place in any case and no
post-procedural AV-fistula, aneurysm or thrombosis was
detected.
During the first 6 months following implantation pro-
cedure one patient (1/57, 1.75 %) was diagnosed with a re-
current neurologic event. Even though sufficient closure
with neither residual right-to-left shunt nor thrombus for-
mation was diagnosed by transesophageal contrast echo-
cardiography, he suffered most likely from another TIA.
The patient, a 48-year old male, current cigarette smoker
presented with paresthesia in his left fingertips, 3 months
after percutaneous PFO closure. Cranial magnetic reson-
ance imaging, cranial computer tomography as well as
standard electroencephalography and electroneurographic
examination did not show any pathologic findings. Even-
tually the event was seen as a suspicious case of a TIA by
an experienced neurologist.
Follow-up echocardiography excluded thrombus forma-
tion in all other cases as well. Persistent right-to-left shunt
was apparent in three patients, even though quantification
revealed only minimal residual shunt in all three cases
(Fig. 4). One patient, a 69-year-old female, who had under-
gone closure following explicit patient’s wish, was diag-
nosed with paroxysmal atrial fibrillation and antithrombotic
therapy was switched to oral anticoagulation.
Discussion
Our retrospective single-center study shows the Figulla®
Flex II Occluder from Occlutech to be a safe and reliable
Table 1 Baseline Characteristics
Characteristic
Age (yrs) 47.3 ± 1.5
Gender (male sex) 32/57 (56.1 %)
Body-mass index (kg/m2) 26.4 ± 0.8
Arterial Hypertension 23/57 (40.4 %)
Diabetes mellitus 4/57 (7.0 %)
Hypercholesterolemia 24/57 (42.1 %)
Cerebrovascular Event
- TIA 16/57 (28.1 %)
- Stroke 39/57 (68.4 %)
Peripheral embolism 4/57 (7.0 %)
Atrial septum aneurysm 50/55 (90.9 %) a
Significant interatrial right-to-left-shunt 46/50 (92.0 %) b
Values are given n (%), except age and body-mass index given as mean ± SEM,
no record in a2, b7 patients
Fig. 2 Distribution of type of previous paradoxical embolic event
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device for interventional PFO closure. Few studies on
PFO closure were performed using the Occlutech Figulla®
devices, and to our knowledge no reports on the third
generation Figulla® Flex II PFO Occluder are available
[15, 18–20, 22–24].
There were no major periprocedural or in-hospital
complications, especially no vascular complications such
as AV fistula, thrombosis or aneurysm after puncture of
a femoral vein and patients were dismissed within the
first 4 days after implantation procedure. Other formerly
reported complications such as device embolization or
intraprocedural TIA did not occur as well [20]. All pa-
tients were initially treated with the same combination
of anti-platelet therapy in form of aspirin 100 mg/die
and clopidogrel 75 mg/die.
Complete data from transesophageal contrast echocar-
diography, performed 6 months post implantation, was
available in 94.7 % of all cases. Examinations did not re-
veal any thrombus formation. Minimal residual right-to-
left shunting was seen in only three cases and did not
require intervention. Considering sufficient closure to be
defined as no or only minimal residual right-to-left
shunting, we were able to reach high sufficient closure
rates using the Figulla® Flex II PFO Occluder when compar-
ing our results to former studies: Using the AmplatzerTM
device Maier et al. reported sufficient closure in 95.9 % in
the PC Trial and Carroll et al. 93.5 % in the RESPECT
Trial, while sufficient closure was achieved in only 86.1 %
in the CLOSURE I Trial studying the STARFlex® device
[9–11]. In previous studies using earlier generation Figulla®
PFO devices closure rates between 83 and 97 % were
reached [18, 20, 23].
Only one patient was diagnosed with atrial fibrillation
within the first 6 months after device implantation.
However, this female patient was 69 years of age. Preva-
lence of atrial fibrillation is known to increase with age
and was shown to be up to 2.7 % in female patients at
that age [25, 26]. Considering this data a clear dependency
of the new onset atrial fibrillation and the device implant-
ation is unlikely. In all other cases antithrombotic therapy
was discontinued after the period of 6 months post closure
procedure, as long as no other indication for an anti-
platelet treatment was apparent.
One recurrent neurologic event within the first 6 months
following PFO closure occurred. The occluder device pro-
vided sufficient closure and thrombus formation could be
precluded by transesophageal contrast echocardiography.
Since further examinations did not reveal pathologies, the
reported symptoms of the 48-year old male patient, a
current smoker, were interpreted as a suspicious case of a
TIA. However, a direct association to the occluder device
is questionable. Furthermore, the event rate is in range of
Fig. 3 Distribution of right-to-left shunt size before interventional PFO closure
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former studies with different occluder devices as listed in
Table 2. Using the AmplatzerTM device Carroll et al. and
Maier et al. reported recurrent neurologic events in 3 % of
all PFO closures in the RESPECT Trial respectively PC
Trial, while recurrent neurologic events occurred in 6 %
after PFO closure with the STARFlex® in the CLOSURE I
Trial [9–11]. Similar results were reported in a study,
which was performed at our department, using the
AmplatzerTM device [27]. Though, the shorter follow-up
period in our present study must be considered.
Since almost all patients presented with a coexisting
ASA conclusions are limited to this patient subgroup.
Former studies revealed that especially these patients are
at risk for a recurrent cerebral ischemia [4, 5]. The RE-
SPECT Trial showed a favorable outcome of percutaneous
PFO closure in patients with ASA and substantial right-
to-left interatrial shunt [9]. The main limitations of our
study are its retrospective design and the relatively short
observation period as well as the fact that three patients
had refused TEE follow up, however a telephone interview
was performed and no event reported.
Conclusions
In conclusion, the Figulla® Flex II PFO Occluder and its
delivery system are safe and provide sufficient closure of
intra-atrial communication in patients with PFO and
ASA, who had suffered from cryptogenic stroke, TIA or
paradoxical peripheral embolism, comparable to former
studies with the AmplatzerTM Occluder systems.
Fig. 4 Distribution of right-to-left shunt 6 months after interventional PFO closure
Table 2 Recurrent Neurologic Event Rate
Study TIA Ischemic Stroke Follow-Up Period
RESPECT Trial (AmplatzerTM)9 6/499 (1.2 %) 9/499 (1.8 %) 2.6 years (mean)
PC Trial (AmplatzerTM)11 5/204 (2.5 %) 1/204 (0.5 %) 4.1 years (mean)
CLOSURE I Trial (STARFlex®)10 13/447 (3.1 %)a 12/447 (2.9)a 2 years
Fischer et al. (AmplatzerTM)27 2/113 (1.8 %) 1/113 (0.9 %) 17.7 months (mean)
Krizianic et al. (Figulla® N)23 0/34 (0 %) 1/34 (2.9 %) 6 months
Aytemir et al. (Figulla®)19 1/85 (1.2 %) 0/85 (0 %) 17.0 months (mean)
aIntention-to-treat-population
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